HIKAL - Hikal
📢 Recent Corporate Announcements
Castilia Life Sciences Private Limited, a key member of Hikal's promoter group, has successfully converted into a Limited Liability Partnership (LLP) named Castilia Life Sciences LLP. As a result of this corporate restructuring, 3,02,31,914 equity shares, representing a 24.52% stake in Hikal, have been vested in the new LLP entity. The Ministry of Corporate Affairs approved this conversion on February 17, 2026. This is a technical change in the legal structure of the promoter entity and does not represent a sale of shares in the open market or a change in the ultimate promoter control.
- Conversion of promoter entity Castilia Life Sciences Private Limited into Castilia Life Sciences LLP.
- Vesting of 3,02,31,914 equity shares of Hikal Limited into the successor LLP entity.
- The transaction involves a significant 24.52% of the company's total shareholding.
- Restructuring approved by the Ministry of Corporate Affairs with a certificate dated February 17, 2026.
- No change in the overall promoter group's aggregate holding or beneficial ownership.
Hikal Limited has announced that its promoter group entity, Castilia Life Sciences Private Limited, has converted into a Limited Liability Partnership (LLP). The Ministry of Corporate Affairs approved this conversion on February 17, 2026, and issued the registration certificate. Consequently, all assets, liabilities, and the entity's shareholding in Hikal have vested in the newly formed Castilia Life Sciences LLP. This transition represents an internal structural change within the promoter group and does not involve any market sale of shares.
- Castilia Life Sciences Private Limited converted to Castilia Life Sciences LLP effective February 17, 2026.
- All assets and shareholding in Hikal Limited have been vested in the new LLP entity.
- The conversion was approved by the Ministry of Corporate Affairs with a Certificate of Registration issued.
- Disclosure made in compliance with Regulations 30 and 30A of SEBI Listing Regulations.
Hikal reported a recovery in Q3 FY26 with consolidated revenue of ₹494 crores and a significantly improved EBITDA margin of 16.8%, driven by the Pharmaceutical segment's return to operational normalcy. The company declared an interim dividend of ₹0.2 per share despite a reported loss caused by a one-time exceptional charge of ₹38 crores related to new labor code provisions. While the Pharma division saw revenue of ₹337 crores, the Crop Protection business at ₹157 crores continues to face pricing headwinds from Chinese overcapacity. Management expects a stronger Q4 as remediation efforts regarding US FDA audits are nearly complete and new capacities become operational.
- Q3 FY26 EBITDA stood at ₹83 crores with margins expanding to 16.8% compared to the 9M average of 9.6%
- Pharmaceutical segment revenue reached ₹337 crores with a 12.3% EBIT margin as supply resumed post-remediation
- A one-time exceptional charge of ₹38 crores for labor code compliance impacted the bottom line, though adjusted PBT grew 21%
- Debt-equity ratio remains stable at 0.58 with ₹100 crore capex spent during the first nine months of FY26
- Diversification into Personal Care is underway with 3-4 products expected to commercialize in FY27
Hikal Limited has declared an interim dividend of ₹0.20 per equity share (10% of face value) for the financial year 2025-26. The company has fixed February 17, 2026, as the record date to identify eligible shareholders, with the dividend payment scheduled to be completed by March 12, 2026. Investors are required to submit necessary tax documentation by February 18, 2026, to ensure appropriate Tax Deduction at Source (TDS) rates are applied. The standard TDS rate for resident shareholders with a valid PAN is 10%, provided the dividend exceeds ₹10,000.
- Interim dividend of ₹0.20 per equity share (10% on face value of ₹2) for FY 2025-26.
- Record date for dividend eligibility is fixed as February 17, 2026.
- Dividend payment to be processed on or before March 12, 2026.
- TDS of 10% for residents with PAN; 20% for those without valid PAN or non-residents without treaty benefits.
- Deadline for submitting tax exemption forms (15G/15H/TRC) is February 18, 2026.
Hikal Limited has officially released the audio recording of its earnings conference call for the third quarter and nine months ended December 31, 2025. The call, conducted on February 11, 2026, provides detailed management commentary on the company's financial health and operational progress. This disclosure is in line with SEBI's transparency requirements for listed entities. Investors can access the recording via the company's investor relations portal to evaluate the management's outlook and strategic updates.
- Audio recording for Q3 and 9M FY26 earnings call is now accessible on the company website.
- The conference call was held on February 11, 2026, following the quarterly results announcement.
- Compliance with SEBI Regulation 30(6) regarding disclosure of institutional investor meetings.
- The recording covers performance details for the nine-month period ending December 31, 2025.
Hikal Limited has updated its internal code of conduct regarding the regulation and monitoring of trading by designated persons. This amendment is in accordance with Regulation 8(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. The move aims to strengthen corporate governance and ensure compliance with the latest regulatory standards. The updated code is now available on the company's official website for public access.
- Amendment to the Code of Internal Procedures and Conduct for trading by designated persons.
- Compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, specifically Regulation 8(2).
- Updated document made available on the company's corporate governance webpage.
- The filing was submitted to BSE and NSE on February 11, 2026.
Hikal Limited has announced Tuesday, February 17, 2026, as the record date for determining shareholder eligibility for an interim dividend for the financial year 2025-26. The decision was finalized during a board meeting held on February 11, 2026. This corporate action confirms the company's intent to distribute profits to its shareholders for the current fiscal year. Investors must hold the company's equity shares in their demat accounts by this date to qualify for the payout.
- Record date for interim dividend fixed as February 17, 2026
- Dividend pertains to the Financial Year 2025-26
- Board approval for the dividend was granted on February 11, 2026
- Applicable for equity shareholders on both BSE (524735) and NSE (HIKAL)
Hikal reported a 10% YoY revenue growth to ₹494 crore in Q3 FY26, driven by a recovery in the Pharmaceutical segment which grew to ₹337 crore. EBITDA increased by 15% to ₹83 crore with margins expanding by 70 bps to 16.8%, despite an exceptional charge of ₹38 crore for labor code implementation. The company has substantially completed US FDA remediation measures and expects a strong Q4 performance. The board also approved a 10% interim dividend, reflecting confidence in the recovery phase.
- Consolidated Revenue grew 10% YoY to ₹494 Cr, while EBITDA rose 15% to ₹83 Cr.
- EBITDA margins improved by 70 bps YoY to 16.8% due to operational efficiencies.
- Pharmaceutical segment revenue rebounded to ₹337 Cr as supply deferrals from H1 were addressed.
- Exceptional item of ₹38 Cr recorded for the implementation of the new Labour Code.
- Interim dividend of 10% of Face Value approved by the Board.
Hikal reported a strong sequential recovery in Q3 FY26 with revenue reaching ₹494 crore, a 55% increase over Q2 FY26, driven by the resumption of supplies in the Pharmaceutical segment following regulatory remediation. EBITDA grew 15% YoY to ₹83 crore, though the bottom line was impacted by a ₹38 crore exceptional charge related to the new labor code, resulting in a net loss of ₹6 crore. The Pharmaceutical division saw a significant rebound with ₹337 crore in revenue, while the Crop Protection segment remains under pressure due to global pricing challenges. Management indicates that the foundation for a stronger FY27 is in place with new high-potency labs and pilot plants becoming operational.
- Q3 Revenue grew 55% QoQ to ₹494 crore, signaling a recovery from H1 regulatory deferrals.
- Pharmaceutical segment revenue rose to ₹337 crore with an EBIT margin of 12.3% as remediation measures near completion.
- EBITDA margins improved significantly to 16.8% in Q3 FY26 compared to 2.4% in the previous quarter.
- Recorded a one-time exceptional expense of ₹38 crore due to the implementation of the new labor code.
- Balance sheet remains stable with a Debt-Equity ratio of 0.58x and 9M FY26 revenue at ₹1,193 crore.
Hikal Limited has declared an interim dividend of ₹0.20 per share despite reporting a standalone net loss of ₹59 million for the quarter ended December 2025. The company's financial health is currently under pressure from a ₹380 million exceptional charge related to new labour codes and a USFDA warning letter impacting its Jigani facility. Most significantly, auditors have issued a modified opinion due to an ongoing internal investigation into irregularities regarding the timing of revenue recognition. While revenue for the quarter showed a slight recovery to ₹4,943 million, the nine-month period remains in a loss of ₹633 million.
- Interim dividend of ₹0.20 per equity share (10% of face value) declared with record date of Feb 17, 2026.
- Reported a standalone net loss of ₹59 million in Q3 FY26 versus a profit of ₹173 million in the same quarter last year.
- Auditors issued a modified opinion citing inability to comment on revenue recognition irregularities pending an internal review.
- Recognized an exceptional item of ₹380 million for gratuity and compensated absences following labour code changes.
- Pharma segment revenue of ₹3,373 million was impacted by customer deferrals following a USFDA warning letter for the Jigani facility.
Hikal Limited reported a 10.4% year-on-year increase in revenue to ₹4,943 million for Q3 FY26, but posted a net loss of ₹59 million compared to a profit of ₹173 million in the previous year. The bottom line was heavily impacted by a ₹380 million exceptional item related to new Labour Codes and a change in the company's gratuity policy. Operational performance in the Pharma segment was hindered by a USFDA warning letter for the Jigani facility, leading to deferred customer purchases. Despite the loss, the company declared an interim dividend of ₹0.20 per share.
- Revenue from operations grew 10.4% YoY to ₹4,943 million, with the Pharma segment contributing ₹3,373 million.
- Reported a net loss of ₹59 million for the quarter, largely due to a ₹380 million exceptional charge for employee benefits and labour code compliance.
- Statutory auditors issued a modified opinion citing ongoing investigations into irregularities regarding the timing of revenue recognition.
- Pharma segment sales were adversely impacted by a USFDA warning letter issued in August 2025 for the Jigani facility.
- Declared an interim dividend of ₹0.20 per equity share (10% of face value) with a record date of February 17, 2026.
Hikal Limited has announced its earnings conference call to discuss financial and operational performance for the quarter and nine months ended December 31, 2025. The call is scheduled for Wednesday, February 11, 2026, at 4:30 PM IST. Senior management, including the Vice Chairman & MD, CFO, and Presidents of the Pharma and Crop Protection divisions, will be present to address investor queries. This is a standard regulatory filing following the conclusion of the third quarter of the fiscal year 2025-26.
- Conference call date: February 11, 2026, at 4:30 PM IST.
- Covers financial results for the quarter and nine-month period ended December 31, 2025.
- Participation from top leadership including Mr. Sameer Hiremath (MD) and Mr. Kuldeep Jain (CFO).
- Universal dial-in numbers provided: +91 22 6280 1309 and +91 22 7115 8210.
Hikal Limited has filed its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the period ending December 31, 2025. The certificate, issued by MUFG Intime India Private Limited (formerly Link Intime), confirms that all securities received for dematerialization were processed within the prescribed timelines. It further validates that the security certificates were mutilated and cancelled after verification, and the names of the depositories were updated in the register of members. This is a standard administrative filing required for all listed companies in India to ensure the integrity of shareholding records.
- Compliance certificate submitted for the quarter ended December 31, 2025.
- Issued by Registrar and Share Transfer Agent (RTA) MUFG Intime India Private Limited.
- Confirms that dematerialized securities are listed on the BSE and NSE.
- Physical certificates were mutilated and cancelled as per SEBI regulatory requirements.
- Verification confirms the substitution of depository names in the register of members.
Hikal Limited has announced the closure of its trading window for all designated persons and their immediate relatives starting January 1, 2026. This move is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the declaration of financial results for the quarter ending December 31, 2025. The window will remain closed until 48 hours after the results are officially announced. This is a standard regulatory procedure for listed companies in India.
- Trading window closure begins on January 1, 2026.
- Closure is related to the financial results for the quarter ending December 31, 2025.
- Window to reopen 48 hours after the declaration of the quarterly financial results.
- Applies to all Designated Persons and their immediate relatives as per SEBI regulations.
Hikal Limited has disclosed irregularities by employees in Sales, Marketing, and Logistics regarding revenue recognition and documentation. The company has already reversed ₹80.7 crore in revenue for Q2FY26 and noted that sales in Q4FY25 and Q1FY26 were inflated by approximately 2% due to these alterations. While the company clarifies that all underlying sales are genuine and no funds were siphoned or embezzled, the timing of revenue recognition was manipulated. This discovery follows a fact-finding review, and the company is now evaluating legal reporting requirements to authorities.
- Identified irregularities in revenue recognition and documentation across Q4FY25, Q1FY26, and Q2FY26.
- Reversed ₹80.7 crore of revenue for the Q2FY26 period following an internal fact-finding review.
- Sales for Q4FY25 and Q1FY26 were approximately 2% higher than actuals due to employee misconduct.
- Management confirms no siphoning or embezzlement of funds; all sales are backed by genuine Customer Purchase Orders.
- Misconduct involved employees in Sales & Marketing, Logistics, and allied operational functions.
Financial Performance
Revenue Growth by Segment
Total revenue for FY25 reached INR 1,859.8 Cr, a 4% YoY increase. The Pharmaceutical segment grew 7.1% YoY to INR 816.8 Cr in 9M FY25, while the Crop Protection segment faced headwinds, recording Q2 FY26 sales of INR 129 Cr. Overall revenue for Q2 FY26 was INR 319 Cr, impacted by a short-term deferral of INR 50 Cr in pharmaceutical orders to the subsequent quarter.
Geographic Revenue Split
Hikal has expanded its market penetration in Latin America and Korea. While specific regional percentage splits are not fully detailed, the company maintains a global footprint with approvals from USFDA (USA), PMDA (Japan), and EDQM (Europe), indicating a high reliance on export markets for its API and CDMO business.
Profitability Margins
Net profit (PAT) for FY25 was INR 90.9 Cr, up from INR 69.5 Cr the previous year. However, Q1 FY26 saw a net loss of INR 22.4 Cr due to order deferments and an EBIT loss of INR 26.1 Cr in the pharma division. Profitability is currently pressured by under-absorption of fixed costs and structural overcapacity in the crop protection industry.
EBITDA Margin
FY25 EBITDA margin stood at 17.9% (INR 333.5 Cr), marking a 24% YoY growth from INR 269.4 Cr. However, margins compressed significantly in Q2 FY26 to an EBITDA of just INR 8 Cr (approx. 2.5% margin) due to deferred sales and high fixed cost bases.
Capital Expenditure
Hikal is executing a significant capex program with planned investments of INR 150 Cr to INR 200 Cr per annum between FY25 and FY27. This follows a historical high-capex cycle, including the commissioning of the Panoli animal health facility in December 2023, aimed at diversifying into high-margin niche segments.
Credit Rating & Borrowing
The company maintains an adequate financial risk profile with a total debt of INR 731.0 Cr as of December 31, 2024, reduced from INR 814.7 Cr in March 2024. Debt protection metrics include a TD/TNW of 0.7x and TOL/TNW of 1.1x as of March 31, 2024.
Operational Drivers
Raw Materials
Key raw materials include chemical intermediates for Gabapentin (Pharma) and Thiabendazole (Crop Protection). Raw material costs are a significant driver, with the company exposed to price volatility that is typically passed through to customers with a 3-6 month lag.
Import Sources
Hikal has a significant dependence on China for raw material stocking. To mitigate this, the company is actively developing alternative vendors in other geographies and domestic sources to ensure supply chain continuity.
Key Suppliers
Not specifically named in the documents, but the company has nearly eliminated reliance on monopolistic suppliers in the Crop division by developing alternate vendors to reduce prices and mitigate supply risks.
Capacity Expansion
Current capacity exceeds 4,100 m3 across 5 manufacturing facilities and 24 production blocks. Planned expansion includes creating additional commercial capacity at the Panoli plant for new molecules being filed in FY26 and FY27 to support dual-filing strategies with the Jigani site.
Raw Material Costs
Profitability remains vulnerable to raw material price volatility. The company utilizes a natural hedge through its own imports to mitigate foreign currency risks associated with material procurement.
Manufacturing Efficiency
The company is focusing on cost leadership and transitioning to a high-margin product mix. However, recent efficiency was hampered by under-absorption of fixed costs during Q2 FY26 when sales were deferred.
Logistics & Distribution
Distribution involves secured transactions with high-risk countries and the implementation of GPS-tracked logistics to ensure high manufacturing compliance standards and product safety.
Strategic Growth
Expected Growth Rate
4%
Growth Strategy
Growth will be driven by the scale-up of the new animal healthcare segment, deeper market penetration in Latin America and Korea, and a shift toward complex chemistry molecules in the CDMO business. The company is also implementing a 'dual filing' strategy for products between its Jigani and Panoli facilities to optimize capacity and mitigate regulatory risks.
Products & Services
Active Pharmaceutical Ingredients (APIs) such as Gabapentin, crop protection chemicals like Thiabendazole, intermediates, and contract development and manufacturing organization (CDMO) services for global innovators.
Brand Portfolio
Hikal operates primarily as a B2B manufacturer and CDMO; specific consumer brand names are not applicable, but it holds a leadership position in the Gabapentin and Thiabendazole markets.
New Products/Services
New molecules in the animal health and specialty chemicals segments are expected to contribute to higher margin revenue in the mid-to-long term, with several RFPs currently active from global innovators.
Market Expansion
Targeting niche CDMO segments and expanding the animal health business following the validation of the Panoli facility. The company is also focusing on increasing its pipeline of complex chemistry molecules.
Market Share & Ranking
Hikal holds a global leadership position in the Thiabendazole market and a dominant position in the Gabapentin market.
Strategic Alliances
Hikal maintains long-standing relationships and exclusive supply contracts with several leading global innovator companies in both the pharmaceutical and crop protection sectors.
External Factors
Industry Trends
The industry is seeing a shift toward CDMO models and animal health. While the crop protection sector is currently struggling with 15-17% margin levels compared to historical 18-19% due to overcapacity, long-term demand for complex molecules remains robust.
Competitive Landscape
Faces intense competition from global chemical manufacturers and Chinese suppliers, particularly in generic APIs and standard crop protection chemicals.
Competitive Moat
Moat is built on long-term contracts, global regulatory approvals (USFDA, etc.), and leadership in specific molecules like Gabapentin. This is sustainable due to high switching costs in contract manufacturing and stringent quality requirements.
Macro Economic Sensitivity
Sensitive to global trade policies and evolving environmental regulations which add volatility to supply chains and procurement cycles.
Consumer Behavior
Increased demand for product safety and supply chain transparency from global innovators is driving Hikal to enhance its digital reporting and compliance systems.
Geopolitical Risks
High risk associated with geographic concentration of suppliers in China; geopolitical shifts could interrupt the flow of key intermediates.
Regulatory & Governance
Industry Regulations
Operations are governed by global standards including USFDA, TGA-GMP (Australia), and PMDA (Japan). The company must also comply with local pollution norms and GPS tracking mandates for hazardous material transport.
Environmental Compliance
Hikal is strengthening SOPs and compliance policies. It has faced a penalty of INR 17.45 Cr from the NGT regarding environmental violations, which it is currently contesting.
Taxation Policy Impact
Not specifically detailed, but the company is subject to standard Indian corporate tax rates and fiscal policies affecting the chemical export sector.
Legal Contingencies
Pending litigation includes a gas leak accident case in Surat (Sachin GIDC). The NGT imposed a penalty of INR 17.45 Cr in October 2022; the matter is currently sub judice before the Supreme Court.
Risk Analysis
Key Uncertainties
The primary uncertainty is the timeline for the stabilization of the crop protection industry and the final outcome of the Surat gas leak litigation, which could impact future customer audits.
Geographic Concentration Risk
Significant operational concentration in India (Gujarat and Karnataka) with high revenue dependency on global exports and raw material dependency on China.
Third Party Dependencies
High dependency on global innovators for CDMO contracts and on Chinese suppliers for key intermediates, though the latter is being actively diversified.
Technology Obsolescence Risk
Risk is mitigated by continuous investment in complex chemistry and the development of new manufacturing blocks capable of handling advanced processes.
Credit & Counterparty Risk
Maintains an adequate liquidity position with unutilized fund-based limits of INR 170 Cr to INR 200 Cr to manage receivable cycles and operational needs.